Products

Sipomid® (Siponimod)

Assessments are required prior to initiating Sipomid®. Titration is required for treatment initiation. The recommended maintenance dosage is 2 mg. The recommended maintenance ...

Faxibet plus® ER (Dapagliflozin/Metformin)

Individualize the starting dose based on the patient’s current treatment. Assess renal function before initiating and periodically thereafter. To improve glycemic control, for pa...

Teriflunomide

The recommended dose of Teriflunomide is 7 mg or 14 mg orally once daily. Teriflunomide can be taken with or without food.

Faxibet® (Dapagliflozin)

Dapagliflozin is a Sodium-glucose cotransporter 2 (SGLT2) inhibitor. Dapagliflozin reduces reabsorption of filtered glucose and increases urinary glucose excretion. Dapagliflozin also reduces sodium r...

Rizolung® (Crizotinib)

•Metastatic NSCLC: The recommended dosage is 250 mg orally twice daily. • Systemic ALCL: The recommended dosage is 280 mg/m2 orally twice daily based on body surface area. Unresectab...

Encastry® (enzalutamide)

160 mg (four 40 mg capsules) Enzalutamide administered orally once daily. Enzalutamide can be taken with or without food. Swallow capsules whole, do not chew, dissolve, or open the capsules. ...

TOFAXEL® (Tofacitinib)

Administration Instructions Changes between Tofaxel® and Tofaxel® ER should be made by the healthcare provider. Do not initiate Tofaxel®/ Tofaxel® ER if absolute lymphocyte...

Simerta® (Osimertinib)

Adjuvant treatment of early stage NSCLC: 80 mg orally once daily, with or without food, until disease recurrence, or unacceptable toxicity, or for up to 3 years. Metastatic NSCL...

Vandesa® (Vandetanib)

300 mg once daily. VANDESA® may be taken with or without food. Dosage reduction may be necessary in the event of severe toxicities or QTc interval prolongation. The starting ...

Pazotri® (Pazopanib)

• 800 mg orally once daily without food (at least 1 hour before or 2 hours after a meal). • Baseline moderate hepatic impairment – 200 mg orally once daily. Not recommende...

Regonib®(Regorafenib)

Recommended dose: 160 mg orally, once daily for the first 21 days of each 28-day cycle. -Take REGONIB after a low-fat meal.

For Experts & healthcare professionals

How is technology impacting the quality assurance of our products

in our manufacturing sites many different types of technologies are being implemented to improve the processes of pharmaceutical manufacturing and Quality Assurance which ultimately, creates a safer medicine...

Our focus, high quality targeted medicines

At Kimia Pharmaceuticals, we are focused on medicine development in key cancer areas where there are patient needs. Our goal is to bring much needed new treatments to people with cancer.

Visit our scientific blogs ONCOMED

ASCO 2020 Gastrointestinal Cancers Symposium

Read breaking news and watch expert interviews from most recent american society of c...

2020 Genitourinary Cancers Symposium

Read breaking news and watch expert interviews from most recent american society of c...


ONCOGENE

Molecular Diagnostics in Colorectal Carcinoma

Watch related videos for expert opinions and download guidelines in OncoGene online m...

BCR-ABL mutations and CML treatment

BCR-ABL1 mutations that should NOT be treated with bosutinib, dasatinib or nilotinib ...

For patients & care givers

 

 

Cancer and its treatment can cause physical symptoms and side effects.They can also cause emotional, social, and financial burden.

 Managing these effects is called palliative care or supportive care.


Research shows that palliative care can improve the quality of patient’s life and help their feel more satisfied with the treatment that receive.
The quality of life of patient during treatment is one of the most important concerns we have.

So, our patient care unit is ready to help patients and their families based on their needs.

About Us

 Missin, Vision & Values


Our R and D Strategy


drug export


Careers


All together we are in constant  motion.                           
Cancer can not stop me & you ,Us !

 Kimia Pharmaceutical Co.